Ligand Pharmaceuticals (LGND) Projected to Announce Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Ligand Pharmaceuticals to announce earnings of $1.97 per share and revenue of $60.8710 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals (NASDAQ:LGND) last issued its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $1.63 EPS for the quarter, missing the consensus estimate of $1.84 by ($0.21). Ligand Pharmaceuticals had a return on equity of 16.19% and a net margin of 55.95%.The company had revenue of $51.72 million during the quarter, compared to analysts’ expectations of $59.10 million. During the same quarter last year, the business earned $1.33 earnings per share. The business’s quarterly revenue was up 14.1% on a year-over-year basis. On average, analysts expect Ligand Pharmaceuticals to post $5 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Ligand Pharmaceuticals Stock Up 1.6%

LGND stock opened at $292.04 on Tuesday. Ligand Pharmaceuticals has a fifty-two week low of $131.67 and a fifty-two week high of $326.63. The company has a market capitalization of $5.85 billion, a price-to-earnings ratio of 39.63, a price-to-earnings-growth ratio of 2.84 and a beta of 1.10. The business’s 50 day moving average price is $280.79 and its two-hundred day moving average price is $232.66. The company has a debt-to-equity ratio of 0.45, a quick ratio of 20.95 and a current ratio of 21.28.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $326.00 price target (up from $285.00) on shares of Ligand Pharmaceuticals in a research note on Monday. Stifel Nicolaus boosted their target price on shares of Ligand Pharmaceuticals from $255.00 to $332.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Bank of America upped their target price on shares of Ligand Pharmaceuticals from $266.00 to $388.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Weiss Ratings cut shares of Ligand Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Finally, Royal Bank Of Canada raised their price objective on Ligand Pharmaceuticals from $262.00 to $340.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $326.00.

Insider Activity at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, insider Andrew Reardon sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $313.28, for a total value of $1,566,400.00. Following the completion of the transaction, the insider directly owned 41,514 shares of the company’s stock, valued at approximately $13,005,505.92. The trade was a 10.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jason Haas sold 6,461 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $255.58, for a total transaction of $1,651,302.38. Following the completion of the transaction, the director owned 4,981 shares in the company, valued at approximately $1,273,043.98. This represents a 56.47% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,231 shares of company stock worth $7,754,451 in the last ninety days. 5.60% of the stock is currently owned by company insiders.

Institutional Trading of Ligand Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the business. Invesco Ltd. lifted its holdings in Ligand Pharmaceuticals by 64.6% in the third quarter. Invesco Ltd. now owns 378,295 shares of the biotechnology company’s stock valued at $67,011,000 after acquiring an additional 148,437 shares during the period. Nomura Holdings Inc. bought a new stake in shares of Ligand Pharmaceuticals during the 3rd quarter valued at about $21,498,000. Bank of Montreal Can increased its position in shares of Ligand Pharmaceuticals by 2,096.5% during the 3rd quarter. Bank of Montreal Can now owns 125,769 shares of the biotechnology company’s stock valued at $22,279,000 after purchasing an additional 120,043 shares during the last quarter. UBS Group AG increased its position in shares of Ligand Pharmaceuticals by 234.2% during the 3rd quarter. UBS Group AG now owns 111,986 shares of the biotechnology company’s stock valued at $19,837,000 after purchasing an additional 78,476 shares during the last quarter. Finally, Castleark Management LLC bought a new position in shares of Ligand Pharmaceuticals in the 3rd quarter worth approximately $11,457,000. 91.28% of the stock is currently owned by hedge funds and other institutional investors.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.